Experienced in Congenital Antithrombin 3 Deficiency

Dr. Murat A. Anamur

Oncology | Hematology Oncology | Hematology
Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is
1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C, 
Newburyport, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Congenital Antithrombin 3 Deficiency
Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is
1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C, 
Newburyport, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Murat Anamur is an Oncologist and a Hematologist Oncology provider in Newburyport, Massachusetts. Dr. Anamur is rated as an Experienced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Anal Cancer. Dr. Anamur is currently accepting new patients.

His clinical research consists of participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Winchester Hospital
Northeast Hospital Corporation
Beth Israel Deaconess Medical Center
Anna Jaques Hospital
Lowell General Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Network Health
  • HMO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ASSOCIATED PHYSICIANS OF HARVARD MEDICAL FACULTY PHYSICIANS AT BETH IS
1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C, Newburyport, MA 01950

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
View 14 Less Clinical Trials
Similar Doctors
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Kenneth A. Bauer
Hematology Oncology | Oncology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Kenneth A. Bauer
Hematology Oncology | Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (34.3 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth Bauer is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Bauer is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism (VTE), Embolectomy, and Thrombectomy.

Experienced in Congenital Antithrombin 3 Deficiency
Dr. Jonathan D. Eneman
Hematology Oncology | Hematology | Oncology
Experienced in Congenital Antithrombin 3 Deficiency
Dr. Jonathan D. Eneman
Hematology Oncology | Hematology | Oncology

Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is

1 Wallace Bashaw Way, 2001 Anna Jacques Cancer C, 
Newburyport, MA 
 (0.1 miles away)
978-463-1374
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Eneman is a Hematologist Oncology specialist and a Hematologist in Newburyport, Massachusetts. Dr. Eneman is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast. Dr. Eneman is currently accepting new patients.

Experienced in Congenital Antithrombin 3 Deficiency
Dr. Archana Bhargava
Hematology Oncology | Oncology | Hematology
Experienced in Congenital Antithrombin 3 Deficiency
Dr. Archana Bhargava
Hematology Oncology | Oncology | Hematology

Core Physicians LLC

5 Alumni Dr, 
Exeter, NH 
 (12.0 miles away)
603-580-6457
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Archana Bhargava is a Hematologist Oncology specialist and an Oncologist in Exeter, New Hampshire. Dr. Bhargava is rated as an Advanced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Her top areas of expertise are Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Trabeculectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anamur's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 46 Advanced Conditions
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile